Synthesis and anticancer activity of new carbohydrazide derivatives bearing furan moiety

Fatih TOK ¹, Elif KAYA TILKİ ², Miriş DİKMEN ², Bedia KOÇYİĞİT-KAYMAKÇIOĞLU ¹*:  

¹ Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, Başbüyük 34854, İstanbul, Turkey.  
² Department of Pharmacology, Faculty of Pharmacy, Anadolu University, Tepebaşı 26210, Eskişehir, Turkey.  
* Corresponding Author. E-mail: bkaymakcioglu@marmara.edu.tr (B.K.); Tel. +90-216-777 52 00.  

Received: 20 June 2021 / Revised: 26 July 2021 / Accepted: 15 November 2021

**ABSTRACT:** In this study, some new carbohydrazide derivatives bearing furan moiety were synthesized. All carbohydrazide structures have been characterized by IR, ¹H-NMR and elemental analysis. Anticancer activity of compounds were investigated on A549 human lung cancer and BJ normal fibroblast cells. According to the MTT assay results, all compounds demonstrated the cytotoxic activity on A549 cells with IC₅₀ values of 43.38-342.63 µM except compound 3g. Only the IC₅₀ values of compound 3c was below 400 µM on BJ cells. Especially, compound 3e showed significant anticancer effects on A549 cells with IC₅₀ value of 43.38 µM and also didn’t show cytotoxic effects on normal BJ cells.  

**KEYWORDS:** Amide; furan; anticancer; carbohydrazide.

1. INTRODUCTION

Cancer is one of the major causes of death worldwide [1]. Lung cancer is one of the most common malignancies, accounting for 11.4% of all new cancer cases in the world. It was estimated that lung cancer is the second most common cancer after breast cancer and the leading cause of cancer death by the International Agency for Research on Cancer [2]. It has a particularly poor prognosis, leading to more deaths in European Union and the United States of America than any other malignant disease [3]. Development of identification and treatment are important steps for cancer treatment. However, the requirement for effective and selective chemotherapeutic agents continues.

Furan, a five membered heterocyclic ring, consists of four carbon atoms and one oxygen atom [4]. Furan rings are known their impressive optical properties and excellent charge-transport properties [5]. Therefore furan containing compounds display numerous biological and pharmaceutical properties such as antimicrobial, anticancer, antibacterial and analgesic activity [6-8]. 2,5-Disubstituted furan derivatives are found in many natural products and oxygen atom in furan ring can form hydrogen bond with biological enzymes or receptors [9]. The structures of acylhydrazide are seen in many bioactive molecules [10] and they promise a range of pharmaceutical applications because of their two hydrogen bonding and two electron donor group (-CONHNHC-) [11, 12]. Cui et al., synthesized acylhydrazide derivatives bearing furan ring and reported their significant antitumor activity [13]. Shafeeulla et al., indicated the strong cytotoxic effects of diacylyhydrazine structures they synthesized [14]. Besides, Sun et al., chose acylhydrazide derivatives for antitumor activity due to their unique structure and strong enzyme potency [15].

In this study, it was aimed to be able to find effective and selective molecules for lung cancer treatment. Therefore methyl 5-(4-aminophenyl)furan-2-carboxylate was chosen as starting material for this synthesis and new carbohydrazide derivatives were synthesized. Their anticancer activity on A549 human lung cancer and BJ normal fibroblast cells were evaluated by the MTT test.
2. RESULTS AND DISCUSSION

2.1. Chemistry

The target compounds were obtained at three different steps. Initially, the substituted benzoyl chloride derivatives and methyl 5-(4-aminophenyl)furan-2-carboxylate were dissolved in tetrahydrofuran. The reaction was completed with stirring on a magnetic stirrer for 4 h at 25°C. In the second step, the hydrazide molecules were synthesized from the reaction of ester functional group with hydrazine monohydrate in ethanol for 6 h at 80-90°C. Finally, the hydrazide compounds were treated with different substituted benzoyl chloride in chloroform to get the target compounds (3a-3g) (Figure 1).

![Figure 1. Synthetic protocol of novel compounds. Reactant and Reagent: (i) NaHCO₃, tetrahydrofuran; (ii) hydrazine monohydrate, ethanol; (iii) chloroform, substituted benzoyl chloride.](image)

The target compounds (3a-3g) were elucidated by IR, ¹H-NMR and elemental analysis. In the IR spectra, the NH stretching bands belonging to amide and hydrazide groups were detected at 3103-3390 cm⁻¹. The strong sharp bands from 1633 to 1697 cm⁻¹ were attributed to C=O amide and carbohydrazide stretching vibrations. The aromatic C-H stretching bands were determined at 3003-3041 cm⁻¹. In the ¹H-NMR spectra, three different NH peaks belonging to amide and carbohydrazide groups were observed between δ 10.38 and 10.90 ppm. For example, these NH peaks were demonstrated in the ¹H-NMR spectrum of compound 3e in Figure 2 below. The aromatic protons appeared at δ 7.00-8.41 ppm as multiplet peaks. The elemental analysis of target compounds were in accordance with theoretical values.

![Figure 2. The ¹H-NMR spectrum of compound 3e.](image)
2.2. Biological evaluation

The anticancer activities of compounds were determined against A549 lung cancer cells and BJ normal fibroblast cells by MTT assay. The IC_{50} values of compounds on A549 and BJ cells were given in Table 1.

Table 1. IC_{50} values (µM) of the compounds on different cell lines after 24 h incubation period.

<table>
<thead>
<tr>
<th>Compound</th>
<th>R_1</th>
<th>R_2</th>
<th>IC_{50} values</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>A549</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>-</td>
<td>-</td>
<td>242.41</td>
</tr>
<tr>
<td>3a</td>
<td>F</td>
<td>OCH_3</td>
<td>115.30</td>
</tr>
<tr>
<td>3b</td>
<td>F</td>
<td>F</td>
<td>326.75</td>
</tr>
<tr>
<td>3c</td>
<td>Cl</td>
<td>CH_3</td>
<td>245.65</td>
</tr>
<tr>
<td>3d</td>
<td>Cl</td>
<td>OCH_3</td>
<td>176.00</td>
</tr>
<tr>
<td>3e</td>
<td>F</td>
<td>NO_2</td>
<td>43.38</td>
</tr>
<tr>
<td>3f</td>
<td>F</td>
<td>Cl</td>
<td>342.63</td>
</tr>
<tr>
<td>3g</td>
<td>Cl</td>
<td>NO_2</td>
<td>&gt;400</td>
</tr>
</tbody>
</table>

According to the MTT assay results, the A549 lung cancer cell viability was significantly decreased with all compounds but except 3g. None of the compounds showed cytotoxic effects on BJ normal fibroblast cells except compound 3e. Only the IC_{50} values of compound 3c was below 400 µM on BJ cells. Among these compounds, compound 3e bearing electron withdrawing group (NO_2) and halogen (fluoro) substituents demonstrated significant anti-cancer effects on human A549 lung cancer cells with 43.38 µM IC_{50} value and also didn’t show cytotoxic effects on normal BJ cells. The selectivity index of compounds was also found to be high.

2.3. ADME properties

According to Lipinski rules, molecular weight should be lower than 500; the number of hydrogen bond donors and hydrogen bond acceptors should be less than 5 and 10, respectively. The values of theoretical partition coefficient (cLog P) should be less than the maximum value of 5. Therefore none of the target compounds violated the Lipinski rules. Furthermore, no more than 10 rotatable bonds and topological polar surface area not greater than 140 Å² should be for ideal drug candidate. On the other hand, water solubility play a critical role in drug’s bioavailability. After calculation of Log S values, all compounds were found as moderately soluble (Table 2).

Table 2. Calculated physicochemical properties of the synthesized compounds.

<table>
<thead>
<tr>
<th>Comp.</th>
<th>MW</th>
<th>RB</th>
<th>HA</th>
<th>HD</th>
<th>MR</th>
<th>TPSA</th>
<th>cLog P</th>
<th>Log S</th>
<th>Lipinski</th>
</tr>
</thead>
<tbody>
<tr>
<td>3a</td>
<td>477.87</td>
<td>9</td>
<td>5</td>
<td>3</td>
<td>124.03</td>
<td>124.03</td>
<td>3.42</td>
<td>-5.85</td>
<td>Yes</td>
</tr>
<tr>
<td>3b</td>
<td>473.45</td>
<td>10</td>
<td>6</td>
<td>3</td>
<td>125.51</td>
<td>109.67</td>
<td>2.63</td>
<td>-5.33</td>
<td>Yes</td>
</tr>
<tr>
<td>3c</td>
<td>461.42</td>
<td>9</td>
<td>4</td>
<td>3</td>
<td>118.98</td>
<td>100.44</td>
<td>3.32</td>
<td>-5.42</td>
<td>Yes</td>
</tr>
<tr>
<td>3d</td>
<td>473.91</td>
<td>9</td>
<td>4</td>
<td>3</td>
<td>129.04</td>
<td>100.44</td>
<td>3.52</td>
<td>-5.99</td>
<td>Yes</td>
</tr>
<tr>
<td>3e</td>
<td>489.91</td>
<td>10</td>
<td>5</td>
<td>3</td>
<td>130.57</td>
<td>109.67</td>
<td>2.73</td>
<td>-5.77</td>
<td>Yes</td>
</tr>
<tr>
<td>3f</td>
<td>488.42</td>
<td>10</td>
<td>7</td>
<td>3</td>
<td>127.84</td>
<td>146.26</td>
<td>2.03</td>
<td>-5.32</td>
<td>Yes</td>
</tr>
<tr>
<td>3g</td>
<td>504.88</td>
<td>10</td>
<td>6</td>
<td>3</td>
<td>132.90</td>
<td>146.26</td>
<td>2.14</td>
<td>-5.76</td>
<td>Yes</td>
</tr>
</tbody>
</table>

MW: Molecular weight; RB: Number of rotatable bonds; HA: Number of hydrogen acceptors; HD: Number of hydrogen donors; MR: Molar refractivity; TPSA: Topological polar surface area; cLog P: calculated Log P; Log S: Water solubility.

3. CONCLUSION

In the present study, we synthesized novel carbodiazide derivatives bearing furan moiety. All new compounds were characterized by elemental analysis and various spectroscopic methods (FTIR, ^1^H-NMR). Their anticancer activities were investigated on A549 lung cancer cells and normal BJ fibroblasts. The A549 lung cancer cell viability was significantly decreased with all compounds but except compound 3g and conversely, these compounds didn’t show cytotoxic effects on BJ normal fibroblast cells. Compound 3e containing fluoro and nitro substituent showed the best anticancer activity against A549 cell and no toxicity of normal fibroblast BJ. Therefore, this compound could be a lung cancer drug candidate with further development.
4. MATERIALS AND METHODS

4.1. Chemistry

All chemicals and reagents were purchased from Sigma-Aldrich and Merck companies. Thin-layer chromatography (TLC) was performed on Merck silica gel 60 F254 aluminum sheets for the purity of the compounds and the progress of reaction. Melting points were determined using Schmelzpunktbestimmer SMP II basic model. The infrared spectra were recorded on a Shimadzu FTIR 8400S spectrophotometer. The $^1$H-NMR spectra in deuterio dimethyl sulfoxide (DMSO-d$_6$) using TMS as an internal standard were recorded on a Bruker 300 MHz Ultrashield TM. Elemental analyses of compounds (C, H, N) were performed on a VarioMICRO elemental analyzer.

4.1.1. General procedure of preparation of amide derivatives

Methyl 5-(4-aminophenyl)furan-2-carboxylate (1 mmol), tetrahydrofuran (10 mL) and NaHCO$_3$ (3 mmol) were taken in a flask. Substituted benzoyl chloride (1 mmol) was added dropwise to solution of methyl 5-(4-aminophenyl)furan-2-carboxylate. The reaction was refluxed at room temperature for 4 h. The solvent was evaporated under vacuum. The precipitate was filtered, washed with water and crystallized from methanol [16].

4.1.2. General procedure of preparation of hydrazide derivatives

Amide derivative (1 mmol), hydrazine monohydrate (1 mmol) and 15 mL ethanol was taken in a flask. The reaction was refluxed for 6-8 h. After cooling, the precipitate was filtered and recrystallized from methanol [17].

4-Fluoro-N-(4-(5-(hydrazinecarbonyl)furan-2-yl)phenyl)benzamide

White solid; Yield: 65%; m.p. 260-261 °C; IR (v, cm$^{-1}$): 3357, 3125 (N-H), 3059 (C-H), 1662 (C=O), 1599, 1573, 1548, 1456 (aromatic C=C, C-N strech. and N-H bend.), 1327 (C-O), 850 (aromatic C-H bend.). $^1$H-NMR (300 MHz, DMSO-d$_6$): $\delta$ 4.48 (s, 2H, NH), 6.99-8.08 (m, 10H, Ar-H), 9.79-10.40 (2s, 2H, NH); Anal. calcd. for C$_{19}$H$_1$_FN$_3$O$_3$: C, 63.71; H, 4.16; N, 12.38; Found: C, 63.55; H, 4.19; N, 12.44%.

4-Chloro-N-(4-(5-(hydrazinecarbonyl)furan-2-yl)phenyl)benzamide

White solid; Yield: 60%; m.p. 277-279 °C; IR (v, cm$^{-1}$): 3310, 3109 (N-H), 3030 (C-H), 1660 (C=O), 1595, 1517, 1496, 1456 (aromatic C=C, C-N strech. and N-H bend.), 1315 (C-O), 842 (aromatic C-H bend.). $^1$H-NMR (300 MHz, DMSO-d$_6$): $\delta$ 4.42 (s, 2H, NH), 7.03-8.22 (m, 10H, Ar-H), 9.66-10.46 (2s, 2H, NH); Anal. calcd. for C$_{19}$H$_1$_ClN$_3$O$_3$: C, 60.77; H, 3.97; N, 11.81; Found: C, 60.87; H, 3.94; N, 11.87%.

4.1.3. General procedure of preparation of carbohydrazide derivatives

Substituted benzoyl chloride (0.5 mmol) and hydrazide derivative (0.5 mmol) were taken in a flask. Chloroform (15 mL) was added into the mixture. The reaction was refluxed for 8 h. The solvent was evaporated under vacuum and the precipitate was filtered and recrystallized from ethanol [18].

4-Fluoro-N-[4-(5-(2-(4-methoxybenzoyl)hydrazinecarbonyl)furan-2-yl)phenyl]benzamide (3a)

Light yellow solid; Yield: 75%; m.p. 226-227°C; IR (v, cm$^{-1}$): 3385, 3115 (N-H), 3005 (aromatic C-H), 2975, 2839 (aliphatic C-H), 1687, 1650 (C=O), 1593, 1519, 1487, 1456 (aromatic C=C, C-N strech. and N-H bend.), 1311 (C-O), 835 (aromatic C-H bend.). $^1$H-NMR (300 MHz, DMSO-d$_6$): $\delta$ 3.84 (s, 3H, OCH$_3$), 7.34-8.02 (m, 14H, Ar-H), 10.49-10.63 (3s, 3H, NH); Anal. calcd. for C$_{36}$H$_{20}$F$_3$N$_5$O$_8$: C, 65.96; H, 4.26; N, 8.88; Found: C, 65.80; H, 4.30; N, 8.95%.

4-Fluoro-N-[4-(5-(2-(4-fluorobenzoyl)hydrazinecarbonyl)furan-2-yl)phenyl]benzamide (3b)

Light yellow solid; Yield: 72%; m.p. 219-220°C; IR (v, cm$^{-1}$): 3319, 3207 (N-H), 3041 (aromatic C-H), 1687, 1633 (C=O), 1599, 1525, 1496, 1456 (aromatic C=C, C-N strech. and N-H bend.), 1325 (C-O), 831 (aromatic C-H bend.). $^1$H-NMR (300 MHz, DMSO-d$_6$): $\delta$ 7.10-8.09 (m, 14H, Ar-H), 10.44-10.57 (3s, 3H, NH); Anal. calcd. for C$_{36}$H$_{20}$F$_2$N$_5$O$_8$: C, 65.08; H, 3.71; N, 9.11; Found: C, 65.25; H, 3.67; N, 9.03%.

4-Chloro-N-[4-(5-(2-(4-methylbenzoyl)hydrazinecarbonyl)furan-2-yl)phenyl]benzamide (3c)
Off-white solid; Yield: 69%; m.p. 234-235°C; IR (v, cm⁻¹): 3284, 3111 (N-H), 3006 (aromatic C-H), 2960, 2856 (aliphatic C-H), 1680, 1643 (C=O), 1591, 1531, 1479, 1456 (aromatic C=C, C-N strech. and N-H bend.), 1315 (C-O), 842 (aromatic C-H bend.). ᵃH-NMR (300 MHz, DMSO-d₆): δ 2.30 (s, 3H, CH₃), 7.00-8.10 (m, 14H, Ar-H), 10.38-10.50 (3s, 3H, NH); Anal. calcd. for C₁₇H₁₇ClN₂O₂: C, 65.89; H, 4.25; N, 8.87; Found: C, 65.77; H, 4.23; N, 8.83 %.

4-Chloro-N-[4-(5-(2-(4-methoxybenzoyl)hydrazinocarbonyl)furan-2-yl)phenyl]benzamide (3d)

Off-white solid; Yield: 79%; m.p. 227-228°C; IR (v, cm⁻¹): 3389, 3109 (N-H), 3010 (aromatic C-H), 2950, 2870 (aliphatic C-H), 1697, 1660 (C=O), 1595, 1519, 1459, 1435 (aromatic C=C, C-N strech. and N-H bend.), 1311 (C-O), 835 (aromatic C-H bend.). ᵃH-NMR (300 MHz, DMSO-d₆): δ 3.82 (s, 3H, OCH₃), 7.11-8.02 (m, 14H, Ar-H), 10.50-10.75 (3s, 3H, NH); Anal. calcd. for C₁₉H₁₇ClN₂O₂: C, 63.74; H, 3.51; N, 11.47; Found: C, 63.62; H, 3.54; N, 11.54 %.

4-Fluoro-N-[4-(5-(2-(4-nitrobenzoyl)hydrazinocarbonyl)furan-2-yl)phenyl]benzamide (3e)

Yellow solid; Yield: 82%; m.p. 256-257°C; IR (v, cm⁻¹): 3296, 3117 (N-H), 3024 (aromatic C-H), 1681, 1645 (C=O), 1602, 1573, 1525, 1456 (aromatic C=C, C-N strech. and N-H bend.), 1325 (C-O), 825 (aromatic C-H bend.). ᵃH-NMR (300 MHz, DMSO-d₆): δ 7.36-8.41 (m, 14H, Ar-H), 10.44-10.89 (3s, 3H, NH); Anal. calcd. for C₁₉H₁₇FClN₂O₂: C, 61.48; H, 3.51; N, 11.47; Found: C, 61.62; H, 3.54; N, 11.54 %.

4-Fluoro-N-[4-(5-(2-(4-Chlorobenzoyl)hydrazinocarbonyl)furan-2-yl)phenyl]benzamide (3f)

Light yellow solid; Yield: 75%; m.p. 220-221°C; IR (v, cm⁻¹): 3390, 3103 (N-H), 3010 (aromatic C-H), 1695, 1658 (C=O), 1595, 1516, 1487, 1456 (aromatic C=C, C-N strech. and N-H bend.), 1323 (C-O), 833 (aromatic C-H bend.). ᵃH-NMR (300 MHz, DMSO-d₆): δ 7.09-8.09 (m, 14H, Ar-H), 10.44-10.63 (3s, 3H, NH); Anal. calcd. for C₁₉H₁₇ClFClN₂O₂: C, 62.83; H, 3.59; N, 8.79; Found: C, 63.07; H, 3.55; N, 8.85 %.

4-Chloro-N-[4-(5-(2-(4-nitrobenzoyl)hydrazinocarbonyl)furan-2-yl)phenyl]benzamide (3g)

Yellow solid; Yield: 84%; m.p. 212-213°C; IR (v, cm⁻¹): 3389, 3115 (N-H), 3003 (aromatic C-H), 1677, 1660 (C=O), 1595, 1573, 1516, 1456 (aromatic C=C, C-N strech. and N-H bend.), 1311 (C-O), 812 (aromatic C-H bend.). ᵃH-NMR (300 MHz, DMSO-d₆): δ 7.42-8.41 (m, 14H, Ar-H), 10.49-10.90 (3s, 3H, NH); Anal. calcd. for C₁₉H₁₇ClN₂O₂: C, 59.47; H, 3.39; N, 11.10; Found: C, 59.32; H, 3.42; N, 11.14 %.

4.2. Biological Activity

4.2.1. Cell culture

The human lung cancer A549 (ATCC® CCL-185™) and human normal fibroblast BJ (ATCC® CRL-2522®) cell lines were obtained from ATCC® and maintained in 10% fetal bovine serum and 1% penicillin/streptomycin containing RPMI (A549) or EMEM (BJ) medium at 37°C on a humidified incubator with 5% CO₂.

4.2.2. Cell viability assay

Cell viability was evaluated by MTT assay [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay [19, 20], which is based on the reduction of the yellow MTT by the mitochondrial dehydrogenase of intact viable or living cells to a purple formazan product. This reduction happens only when mitochondrial reductase enzymes are active. Therefore, increased purple colour is directly related to the number of viable cells. The amount of purple formazan produced by cells treated with compounds are compared with the amount of formazan produced by untreated control cells.

Cell viability was determined by MTT assay. Briefly, cells were grown in 96-well plates at a density of 3×103 cells per well and subjected to different concentrations of the compounds (1000, 500, 250, 125, 62.5, 31.2, 15.6, 7.8, 3.9 and 1.9 µM). After 24 h incubation, MTT solution was added to reach a final concentration of 0.5 mg/mL. The cells were incubated for another 3 h. Then current medium was removed and 100 µL of DMSO solution was added. The absorbance was measured at 540 nm using a Cytation 3 Cell Imaging Multi-Mode Reader (Bio-Tek). Cell survival rates were expressed as the percentage of the DMSO (0.1%) solvent control.
4.3. ADME properties

All synthesized compounds were evaluated for their physicochemical properties using Swissadme online server (http://www.swiss.adme.ch/) for calculations [21]. Furthermore, drug-like properties such as Lipinski rule of five of all compounds were tested also.

Acknowledgements: This research was partly presented at the 6th BBBBB Conference on Pharmaceutical Sciences, 10-12 September, 2015, Helsinki, Finland.


Conflict of interest statement: The authors declared no conflict of interest.


